Desktop version

Home arrow Sociology

  • Increase font
  • Decrease font


<<   CONTENTS   >>

Non-Drug Therapies

Managing fibromyalgia symptoms with medications is only a part of the multidisciplinary approach that is needed to address this disease. Non-drug therapies also play an important role in the overall treatment plan for fibromyalgia. Physical exercise and cognitive behavioral therapy (CBT) are the two most studied non-pharmacologic interventions for fibromyalgia.

Additional interventions that are used include yoga, tai chi, qi gong, mindfulness, acupuncture, and biofeedback.

Physical exercise has been shown to be beneficial for pain control, sleep, mood, and stress and should be used in addition to any drug treatment. Low-impact physical exercises are typically started slowly and increased gradually based on the individual. A meta-analysis of randomized clinical trials looking at the effectiveness of therapeutic exercise in fibromyalgia found evidence to suggest that muscle strengthening and aerobic exercise are most effective in reducing the pain and severity of the disease. Stretching and aerobic exercise produce the largest improvements in health- related quality of life, and combined exercise was the most effective way of reducing symptoms of depression.184

Water-based exercises are also beneficial and can decrease pain and improve strength and stamina. A 16-week randomized controlled study assessing the effects of aquatic therapy in patients with heightened fibromyalgia symptoms showed that exercise therapy three times a week in a warm pool improved most symptoms.185

Cognitive behavioral therapy focuses on understanding how thoughts and behaviors can affect pain and other symptoms.2 Cognitive behavioral therapy and related treatment, such as mindfulness, can be helpful for patients for symptom control and to lessen the pain that they experience. A Cochrane review of CBTs for fibromyalgia found that CBTs provided some benefit in reducing pain, negative mood, and disability.186 Cognitive behavior therapy has also been found to be beneficial in reducing pain catastrophizing in patients with fibromyalgia.187

Mind–Body Practices

Yoga is a mind body technique that uses physical postures in combination with breathing techniques and meditation. A meta-analysis of 3 yoga trials in 86 fibromyalgia patients showed positive effects on reducing sleep disturbances, fatigue, depression, improving quality of life, and providing pain relief.188

Tai chi is a traditional Chinese practice that combines meditation with deep breathing, relaxation, and gentle movements. A meta-analysis of 6 randomized trials in 657 patients with fibromyalgia demonstrated that tai chi had significant positive benefits for pain, sleep quality index, fatigue, depression, and quality of life as assessed by the Fibromyalgia Impact (FIQ) score.189 Tai chi could provide an alternative for the management of fibromyalgia symptoms, especially for patients who are unable to tolerate aerobic exercise.

Qi gong is a holistic type of coordinated body posture and movement, breathing, and meditation used for health in Chinese medicine. Preliminary clinical research shows that external qi gong therapy performed by a trained qi gong practitioner might decrease pain and improve functioning in women with fibromyalgia.190 Other evidence suggests that qi gong sessions three times weekly may improve pain, tender points, and symptom severity in patients with fibromyalgia.191 Since exercise is the best way to manage fibromyalgia, qi gong is a good complementary option for the management of symptoms in fibromyalgia.

Acupuncture is an ancient Chinese practice that uses needles to stimulate specific points throughout the body in an effort to improve overall function. Studies have shown inconsistent results on the effectiveness of this technique for fibromyalgia symptoms. Kim J et al.192 conducted a systematic review and meta-analysis of 8 studies comparing verum and sham acupuncture in 579 patients with fibromyalgia and found that verum acupuncture is more effective than sham acupuncture for pain relief, improving sleep quality, and general status posttreatment. A reduction in fatigue was not found.

Biofeedback is a mind body technique that gives a patient visual or auditory feedback on processes such as heart rate, pain perception, muscle tension, and blood flow. This information is then used by the patient to learn to control stress. While biofeedback has been helpful for some people with fibromyalgia, more studies are needed to confirm its effectiveness.

Conclusion

Fibromyalgia is a challenging disease with a complex etiology yet to be determined. While advancements are being made to understand the pathophysiology, current treatment is focused on symptom management. A multi-modal, patient-specific approach inclusive of medication, in combination with non-pharmacologic therapies, is a necessary part of the treatment plan. Opioids have proven unhelpful in this patient population and should be avoided as they can cause worsening of pain.

References

  • 1. National Fibromyalgia and Chronic Pain Association. Symptoms of fibromyalgia. https://fibroandpain. org/symptoms-2. Accessed 02 December 2019.
  • 2. American College of Rheumatology. Fibromyalgia. https://www.rheumatology.org/I-Am-A/Patient-C aregiver/Diseases-Conditions/Fibromyalgia. Accessed 23 December 2019.
  • 3. National Fibromyalgia and Chronic Pain Association. Diagnosis of fibromyalgia. https://fibroandpain. org/diagnosis-2. Accessed 02 December 2019.
  • 4. Wolfe F., Clauw D.J., Fitzcharles M.A., et al. The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62(5):600—610.
  • 5. Kern K.-U., Schwickert M. Ambroxol for the treatment of fibromyalgia: fact or fiction? J Pain Res 2017:10:1905-1929.
  • 6. Uceyler N., Hauser W„ Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011:12:245.
  • 7. Rodriguez-Pinto I., Agmon-Levin N., Howard A.. Shoenfeld Y. Fibromyalgia and cytokines. Immunol Lett 2014;161(2):200—203.
  • 8. Staud R. Cytokine and immune system abnormalities in fibromyalgia and other central sensitivity syndromes. Curr Rheumatol Rev 2015:11(2): 109—115.
  • 9. Savino W„ Mendes-da-Cruz D.A., Lepletier A., Dardenne M. Hormonal control of T-cell development in health and disease. Nat Rev Endocrinol 2016;12(2):77—89.
  • 10. Malek H., Ebadzadeh M.M., Safabakhsh R., Razavi A., Zaringhalam J. Dynamics of the HPA axis and inflammatory cytokines: insights from mathematical modeling. Comput Biol Med 2015;67:1-12.
  • 11. Gupta D., Morley J.E. Hypothalamic-pituitary-adrenal (HPA) axis and aging. Compr Physiol 2014;4(4):1495—1510.
  • 12. DeLeo J.A., Colburn R.W., Nichols M., Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996;16(9):695-700.
  • 13. Xu X.J., Hao J.X., Andell-Jonsson S., Poli V., Bartfai T., Wiesenfeld-Hallin Z. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine 1997;9(12): 1028-1033.
  • 14. Sommer C., Schmidt C., George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 1998;151(1):138—142.
  • 15. Salemi S., Rethage J., Wollina U., et al. Detection of interleukin lp (IL-lfi), IL-6, and tumor necrosis factor-а in skin of patients with fibromyalgia. J Rheumatol 2003;30(1):146-150.
  • 16. Imamura M., Targino R.A., Hsing W.T.. et al. Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia. Clin Interv Aging 2014;9:939-944.
  • 17. Banfi G., Lombardi G., Colombini A., Melegati G. Whole-body cryotherapy in athletes. Sports Med 2010;40(6):509-517.
  • 18. Hernandez M.E., Becerril E., Perez M., et al. Proinflammatory cytokine levels in fibromyalgia patients are independent of body mass index. BMC Res Notes 2010;3(1):156.
  • 19. Tsilioni I.. Russell I.J.. Stewart J.M.. Gleason R.M.. Theoharides T.C. Neuropeptides CRH, SP. HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 2016;356(3):664-672.
  • 20. Kosek E., Altawil R„ Kadetoff D., et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain: interleukin-8 in fibromyalgia and interleukin-1 p in rheumatoid arthritis. J Neuroimmunol 2015;280:49-55.
  • 21. Kadetoff D., Lampa J., Westman M., Andersson M., Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012;242( 1—2):33—38.
  • 22. Ortega E., Bote M.E., Giraldo E., Garcia J.J. Aquatic exercise improves the monocyte pro- and anti-inflammatory cytokine production balance in fibromyalgia patients. Scand J Med Sci Sports 2012;22(1):104—112.
  • 23. Bote M.E.. Garcia J.J., Hinchado M.D., Ortega E. Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise. PLoS ONE 2013;8(9):e74524.
  • 24. Bote M.E., Garcia J. J., Hinchado M.D., Ortega E. Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 2012;19(6):343—351.
  • 25. Xiao Y.. Haynes W.L.. Michalek J.E.. Russell I.J. Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol lnt 2013;33(5):1259—1264.
  • 26. Iannuccelli C., Di Franco M., Alessandri C., et al. Pathophysiology of fibromyalgia: a comparison with the tension-type headache, a localized pain syndrome. Ann N Y Acad Sci 2010;1193:78—83.
  • 27. Bazzichi L., Rossi A., Massimetti G., et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25(2):225-230.
  • 28. Uceyler N.. Valenza R., Stock M., Schedel R., Sprotte G., Sommer C. Reduced levels of anti inflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006;54(8):2656-2664.
  • 29. Sturgill J., McGee E., Menzies V. Unique cytokine signature in the plasma of patients with fibromyalgia. J Immunol Res 2014:2014:938576.
  • 30. Mendieta D., de la Cruz-Aguilera D.L., Barrera-Villalpando M.I., et al. 1L-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. JNeuroimmunol 2016;290:22-25.
  • 31. Ranzolin A., Duarte A.L., Bredemeier M., et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia: a controlled cross-sectional study. Cytokine 2016:84:25-28.
  • 32. Nakamura T., Schwander S.K., Donnelly R., et al. Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin Vaccin Immunol 2010;17(4):582—587.
  • 33. Behm F.G., Gavin I.M., Karpenko O., et al. Unique immunologic patterns in fibromyalgia. BMC Clin Pathol 2012:12:25.
  • 34. Cordero M.D., Alcocer-Gomez E., Culic O., et al. NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q10. Antioxid Redox Signal 2014:20(8): 1169—1180.
  • 35. Cordero M.D., Alcocer-Gomez E., Marin-AguilarF., et al. Mutation in cytochrome В gene of mitochondrial DNA in a family with fibromyalgia is associated with NLRP3-inflammasome activation. J Med Genet 2016;53(2):113—122.
  • 36. Blanco I., Beritze N., Arguelles M., et al. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010;29( 12): 1403—1412.
  • 37. Ang D.C., Hilligoss J., Stump T. Mast cell stabilizer (ketotifen) in fibromyalgia: phase 1 randomized controlled clinical trial. Clin J Pain. Epub 3 November 2014.
  • 38. Ang D.C., Moore M.N., Hilligoss J., Tabbey R. MCP-1 and IL-8 as pain biomarkers in fibromyalgia: a pilot study. Pain Med 2011 ;12(8): 1154-1161.
  • 39. Feng J., Zhang Z., Wu X., et al. Discovery of potential new gene variants and inflammatory cytokine associations with fibromyalgia syndrome by whole exome sequencing. PLoS ONE 2013;8(6):e65033.
  • 40. Sanchez-Dommguez B., Bullon R, Roman-Malo L., et al. Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with fibromyalgia. Mitochondrion 2015:21:69—75.
  • 41. Meeus M., Nijs J., Hermans L., Goubert D., Calders P. The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opin Titer Targets 2013:17(9): 1081-1089.
  • 42. Bortolato B., Berk M., Maes M„ McIntyre R.S., Carvalho A.F. Fibromyalgia and bipolar disorder: emerging epidemiological associations and shared pathophysiology. Curr Mol Med 2016;16(2):119—136.
  • 43. Akbas A., Inanir A., Benli I., Onder Y., Aydogan L. Evaluation of some antioxidant enzyme activities (SOD and GPX) and their polymorphisms (MnSOD2 Ala9Val. GPX1 Prol98Leu) in fibromyalgia. Eur Rev Med Pharmacol Sci 2014; 18(8): 1199-1203.
  • 44. Fatima G., Das S.K., Mahdi A.A. Some oxidative and antioxidative parameters and their relationship with clinical symptoms in women with fibromyalgia syndrome. Int J Rheum Dis 2015;20(1):39—45.
  • 45. Cordero M.D., De Miguel M., Fernandez A.M., et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010;12(1):R17.
  • 46. Toker A., Kucuksen S., Kucuk A., Cicekler H. Serum ischemia-modified albumin and malondialdehyde levels and superoxide dismutase activity in patients with fibromyalgia. Clin Lab 2014;60(10):1609—1615.
  • 47. Bagis S., Tamer L., Sahin G., et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 2005:25(3): 188—190.
  • 48. Ozgocmen S., Ozyurt H„ Sogut S., Akyol O., Ardicoglu O., Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2006:26(7):598-603.
  • 49. La Rubia M., Rus A.. Molina F., Del Moral M.L. Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status? Clin Exp Rheumatol 2013;31 (6 Suppl 79):S121—S127.
  • 50. Rus A., Molina F., Gasso M., Camacho M.V., Peinado M.A., del Moral M.L. Nitric oxide, inflammation, lipid profile, and cortisol in normal- and overweight women with fibromyalgia. Biol Res Nurs 2016;18(2):138—146.
  • 51. Fatima G., Das S.K., Mahdi A.A. Oxidative stress and antioxidative parameters and metal ion content in patients with fibromyalgia syndrome: implications in the pathogenesis of the disease. Clin Exp Rheumatol 2013;31 (6 Suppl 79):S128-S133.
  • 52. Ozgocmen S., Ozyurt H., Sogut S., Akyol O. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. Rheumatol Int 2006;26(7):585-597.
  • 53. Kim S.K., Kim S.H., Nah S.S., et al. Association of guanosine triphosphate cyclohydrolase 1 gene polymorphisms with fibromyalgia syndrome in a Korean population. J Rheumatol 2013;40(3):316—322.
  • 54. Sendur O.F., Turan Y., Tastaban E., Yenisey C., Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int 2009;29(6):629—633.
  • 55. Cimen O.B., Cimen M.Y., Yapici Y., Camdeviren H. Arginase, NOS activities, and clinical features in fibromyalgia patients. Pain Med 2009;10(5):813—818.
  • 56. Arendt-Nielsen L., Fernandez-de-Las-Penas C„ Graven-Nielsen T. Basic aspects of musculoskeletal pain: from acute to chronic pain. J Man Manip Ther 2011; 19(4): 186-193.
  • 57. DeSantana J.M., Sluka K.A. Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain. Curr Pain Headache Rep 2008; 12(5):338—343.
  • 58. Staud R. Peripheral pain mechanisms in chronic widespread pain. Best Pract Res Clin Rheumatol 2011;25(2):155—164.
  • 59. Joseph E.K., Levine J.D. Hyperalgesic priming is restricted to isolectin B4-positive nociceptors. Neuroscience 2010:169( 1):431-435.
  • 60. Law L.A, Sluka K.A., McMullen T., Lee J., Arendt-Nielsen L., Graven-Nielsen T. Acidic buffer induced muscle pain evokes referred pain and mechanical hyperalgesia in humans. Pain 2008;140(2):254-264.
  • 61. Issberner U., Reeh P.W., Steen K.H. Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia? Neurosci Lett 1996;208(3):191—194.
  • 62. Sluka K.A.. Price M.P., Breese N.M., Stucky C.L., Wemmie J.A., Welsh M.J. Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 2003;106(3):229—239.
  • 63. Yen Y.T.. Tu P.H., Chen C.J., Lin Y.W.. Hsieh S.T., Chen C.C. Role of acid-sensing ion channel 3 in sub- acute-phase inflammation. Mol Pain 2009;5:1.
  • 64. Alvarez P. Green P.G., Levine J.D. Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat. Pain 2014;155(6):1161—1167.
  • 65. Cagnie B., Coppieters I., Denecker S., Six J.. Danneels L., Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthritis Rheum 2014;44(1):68—75.
  • 66. Nielsen L.A., Henriksson K.G. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition. Best Pract Res Clin Rheumatol 2007;21(3):465-480.
  • 67. Desmeules J.A., Cedraschi C., Rapiti E., et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003:48(5): 1420—1429.
  • 68. Vierck C.J.. Wong F., King C.D., Mauderli A.P., Schmidt S., Riley J.L., III. Characteristics of sensitization associated with chronic pain conditions. Clin J Pain 2014;30(2):119—128.
  • 69. Chen W.N., Lee C.H.. Lin S.H., et al. Roles of ASIC3, TRPV1. and NaV1.8 in the transition from acute to chronic pain in a mouse model of fibromyalgia. Mol Pain 2014;10:40.
  • 70. Bazzichi L., Giacomelli C., Consensi A., et al. One year in review 2016: fibromyalgia. Clin Exp Rheumatol 2016;34(2 Suppl 96):S145-S149.
  • 71. Lefaucheur J.P. The ‘paradox’ of neuropathic pain associated with small-fiber lesions in the context of fibromyalgia. Pain 2016:157(6): 1364—1365.
  • 72. Gauffin J., Hankama T., Kautiainen H., Hannonen P, Haanpaa M. Neuropathic pain and use of pain detect in patients with fibromyalgia: a cohort study. BMC Neurol 2013:13:21.
  • 73. Koroschetz J., Rehm S.E., Gockel U., et al. Fibromyalgia and neuropathic pain - Differences and similarities: a comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurol 2011:11:55.
  • 74. Littlejohn G. Neuroinflammation in fibromyalgia and CRPS: top-down or bottom-up? Nat Rev Rheumatol 2016;12(4):242.
  • 75. Cassisi G., Sarzi-Puttini P, Casale R., et al. Pain in fibromyalgia and related conditions. Reumatismo 2014:66(1 ):72-86.
  • 76. Sumpton J.E., Moulin D.E. Fibromyalgia. Handb Clin Neurol 2014:119:513-527.
  • 77. Brusselmans G., Nogueira H., De Schamphelaere E., Devulder J., Crombez G. Skin temperature during cold pressor test in fibromyalgia: an evaluation of the autonomic nervous system? Acta Anaesthesiol Belg 2015:66(1): 19-27.
  • 78. Gerhardt A., Eich W., Janke S., Leisner S., Treede R.D., Tesarz J. Chronic widespread back pain is distinct from chronic local back pain: evidence from quantitative sensory testing, pain drawings, and psychometrics. Clin J Pain 2016;32(7):568—579.
  • 79. Blumenstiel K., Gerhardt A., Rolke R., et al. Quantitative sensory testing profiles in chronic back pain are distinct from those in fibromyalgia. Clin J Pain 2011 ;27(8):682—690.
  • 80. Ramirez M., Martmez-Martinez L.A., Hernandez-Quintela E., Velazco-Casapia J., Vargas A., Martinez- Lavin M. Small fiber neuropathy in women with fibromyalgia: an in vivo assessment using corneal con- focal bio-microscopy. Semin Arthritis Rheum 2015;45(2):214—219.
  • 81. Garcia-Martin E., Garcia-Campayo J., Puebla-Guedea M., et al. Fibromyalgia is correlated with retinal nerve fiber layer thinning. PLoS ONE 2016:1 l(9):e0161574.
  • 82. Kosmidis M.L., Koutsogeorgopoulou L., Alexopoulos H., et al. Reduction of intraepidermal nerve fiber density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study. J Neurol Sci 2014:347(1-2): 143-147.
  • 83. Uceyler N., Sommer C. Reply: small fibre neuropathy, fibromyalgia and dorsal root ganglia sodium channels. Brain 2013; 136(9):e247.
  • 84. Doppler K., Rittner H.L., Deckart M., Sommer C. Reduced dermal nerve fiber diameter in skin biopsies of patients with fibromyalgia. Pain 2015:156(11):2319—2325.
  • 85. de Tommaso M., Nolano M., Iannone F., et al. Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features. J Neurol 2014;261(3):461—472.
  • 86. Okifuji A., Bradshaw D.H., Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 2009;28(4):475-478.
  • 87. Lerma C., Martinez A., Ruiz N., Vargas A., Infante O., Martinez-Lavin M. Nocturnal heart rate variability parameters as potential fibromyalgia biomarker: correlation with symptoms severity. Arthritis Res Ther 2011 ;13(6):R 185.
  • 88. Martinez-Lavin M., Vidal M., Barbosa R.E., Pineda C., Casanova J.M., Nava A. Norepinephrine-evoked pain in fibromyalgia: randomized pilot study. BMC Musculoskelet Disord 2002;3:2.
  • 89. Martinez-Lavin M., Solano C. Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain. Med Hypotheses 2009;72(l):64-66.
  • 90. Giir A., Oktayoglu P. Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008:12(3): 175—181.
  • 91. Staud R. Fibromyalgia pain: do we know the source? Curr Opin Rheumatol 2004; 16(2): 157—163.
  • 92. Albrecht D., Protsenko E., Mawla I., et al. Does brain glial activation have a role in fibromyalgia? A PBR28 PET study. Poster presented at 16th World Congress on Pain. 26-30 September 2016: Yokohama, Japan.
  • 93. Kosek E., Martinsen S., Gerdle B., et al. The translocator protein gene is associated with symptom severity and cerebral pain processing in fibromyalgia. Brain Behav Immun 2016;58:218-227.
  • 94. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10(l):23-36.
  • 95. Watkins L.R., Maier S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 2005:257(2): 139-155.
  • 96. Qiao H., Zhang Q., Yuan H., et al. Elevated neuronal a-synuclein promotes microglia activation after spinal cord ischemic/reperfused injury. NeuroReport 2015;26( 11):656—661.
  • 97. Klein C.P., Sperotto N.D., Maciel I.S., Leite C.E., Souza A.H., Campos M.M. Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology 2014:86:57-66.
  • 98. Albrecht D.S., MacKie P.J., Kareken D.A., et al. Differential dopamine function in fibromyalgia. Brain Imaging Behav 2016:10(3):829—839.

99. Ledermann K., Jenewein J„ Sprott H., et al. Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression: a [11C] raclopride PET-study. Eur

Neuropsychopharmacol 2016;26(2):320—330.

  • 100. Cordero M.D., Moreno-Fernandez A.M., Carmona-Lopez M.I., et al. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem 2010;43(13-14):1174-1176.
  • 101. Cordero M.D., Dfaz-Parrado E., Carrion A.M., et al. Is inflammation a mitochondrial dysfunction- dependent event in fibromyalgia? Antioxid Redox Signal 2013;18(7):800—807.
  • 102. Bettoni L., Bonomi F.G., Zani V., et al. Effects of 15 consecutive cryotherapy sessions on the clinical output of fibromyalgic patients. Clin Rheumatol 2013;32(9): 1337—1345.
  • 103. Culic O., Cordero M.D., Zanic-Grubisic T., et al. Serum activities of adenosine deaminase, dipepti- dyl peptidase IV and prolyl endopeptidase in patients with fibromyalgia: diagnostic implications. Clin Rheumatol 2016;35( 10):2565-2571.
  • 104. Ortega E., Garcia J.J., Bote M.E., et al. Exercise in fibromyalgia and related inflammatory disorders: known effects and unknown chances. Exerc Immunol Rev 2009:15:42-65.
  • 105. Geiss A..RohlederN., Anton F. Evidence foran association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology 2012;37(5 ):671 -684.
  • 106. Vargas-Alarcon G„ Alvarez-Leon E., Fragoso J.M., et al.. A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia. BMC Musculoskelet Disord 2012:13:23.
  • 107. Martinez-Lavin M. Small fibre neuropathy, fibromyalgia and dorsal root ganglia sodium channels. Brain 2013;136(9):e246.
  • 108. Akopian A.N., Sivilotti L., Wood J.N. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 1996:379(6562):257—262.
  • 109. Zimmermann K., Leffler A.. Babes A., et al. Sensory neuron sodium channel Navi.8 is essential for pain at low temperatures. Nature 2007:447(7146):855-858.
  • 110. Blair N.T., Bean B.P. Roles of tetrodotoxin (TTX)-sensitive Na-i- current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J Neurosci 2002:22(23): 10277-10290.
  • 111. Renganathan M., Cummins T.R., Waxman S.G. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 2001;86(2):629-640.
  • 112. Kinloch R.A., Cox RJ. New targets for neuropathic pain therapeutics. Expert Opin Ther Targets 2005;9(4):685-698.
  • 113. Coggeshall R.E., Tate S., Carlton S.M. Differential expression of tetrodotoxin-resistant sodium channels Navi.8 and Navl.9 in normal and inflamed rats. Neurosci Lett 2004;355(l-2):45-48.
  • 114. Strickland I.T., Martindale J.C., Woodhams P.L., Reeve A.J., Chessell I.P., McQueen D.S. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain 2008;12(5):564-572.
  • 115. Huang J., Yang Y., Zhao P., et al. Small-fiber neuropathy Navi.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci 2013:33(35): 14087-14097.
  • 116. Lai J., Gold M.S., Kim C.S., et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel. NaV1.8. Pain 2002:95(1-2): 143-152.
  • 117. Joshi S.K., Mikusa J.P., Hernandez G., et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain 2006;123(1—2):75—82.
  • 118. Akopian A.N., Souslova V., England S., et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999;2(6):541 —548.
  • 119. Roza C„ Laird J.M., Souslova V., Wood J.N., Cervero F. The tetrodotoxin-resistant Na-i- channel Navi.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol 2003;550(3):921-926.
  • 120. Abrahamsen B., Zhao J., Asante C.O., et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science 2008;321(5889):702-705.
  • 121. Han C., Vasylyev D., Macala L.J., et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry 2014;85(5):499—505.
  • 122. Bagal S.K., Chapman M.L., Marron B.E., Prime R., Storer R.I., Swain N.A. Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett 2014;24(16):3690-3699.
  • 123. Dabby R., Sadeh M., Broitman Y., Yosovich K., Dickman R., Leshinsky-Silver E. Painful small fiber neuropathy with gastroparesis: a new phenotype with a novel mutation in the SCN10A gene. J Clin Neurosci 2016:26:84—88.
  • 124. Brouwer B.A., Merkies I.S., Gerrits M.M., Waxman S.G., Hoeijmakers J.G., Faber C.G. Painful neuropathies: the emerging role of sodium channelopathies. J Periplier Nerv Syst 2014:19(2):53—65.
  • 125. Minerbi A., Gonzalez E., Brereton N.. et al. Altered microbiome composition in individuals with fibromyalgia. Pain 2019:160(11):2589-2602.
  • 126. Goebel A.. Buhner S., Schedel R., Lochs H., Sprotte G. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Rheumatol OxfEngl 2008:47(81:1223-1227.
  • 127. Fitzcharles M.A., Ste-Marie P.A., Gamsa A., Ware M.A.. Shir Y. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med 2011:124(101:955-960.
  • 128. Wright C.L., Mist S.D., Ross R.L., Jones K.D. Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immunol 2010:6(51:745-756.
  • 129. Northcott M.J., Guymer E.K., Littlejohn G.O. Pharmacological treatment options for fibromyalgia. Clin Phann 2017:9(11). doi: 10.121 l/CP.2017.20203533.
  • 130. Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs 2010;70(1):1-14.
  • 131. Albrecht D.S., Forsberg A., Sandstrom A., et al. Brain glial activation in fibromyalgia-a multi-site positron emission tomography investigation. Brain Behav Immun 2019;75:72-83.
  • 132. Younger J., Parkitny L., McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014;33(4):451 —459.
  • 133. Younger J., Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009:10(41:663—672.
  • 134. Younger J., Noor N„ McCue R., Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthiritis Rheum 2013;65(2):529—538.
  • 135. Wood P.B., Patterson J.C., 2nd, Sunderland J.J., et al. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8(l):51-58.
  • 136. Wood P.B., Schweinhardt P, Jaeger E., et al. Fibromyalgia patients show an abnormal dopamine response to pain. Ear J Neurosci 2007:25(12):3576—3582.
  • 137. Holman A.J. Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia. J Clin Rheumatol 2003;9(4):277—279.
  • 138. Holman A.J., Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005:52(81:2495-2505.
  • 139. Montplaisir J., Nicolas A., Denesle R., Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52(5):938—943.
  • 140. Maihofner C., Schneider S., Bialas P.. Gockel H.. Beer K.G., Bartels M.. Kern K.U. Successful treatment of complex regional pain syndrome with topical ambroxol: a case series. Pain Manag 2018:8(61:427-436.
  • 141. Martfnez-Martmez L.A., Perez L.F., Becerril-Mendoza L.T.. et al. Clin Rheumatol 2017:36(81:1879- 1884. doi:10.1007/sl0067-017-3664-z.
  • 142. Littlejohn G., Guymer E. Modulation of the NMDA receptor activity in fibromyalgia. Biomedicines 2017:5(21:15.
  • 143. Harris R.E. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther 2010;12(5):141.
  • 144. Larson A.A., Giovengo S.L., Russell I.J., Michalek J.E. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000:87(21:201-211.
  • 145. Sorensen J., Bengtsson A., Backman E., Henriksson K.G., Bengtsson M. Pain analysis in patients with fibromyalgia: effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995:24(61:360-365.
  • 146. Sorensen J., Bengtsson A., Ahlner J., Henriksson K.G., Ekselius L., Bengtsson M. Fibromyalgia—Are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997;24(8):1615—1621.
  • 147. Graven-Nielsen T., Aspegren Kendall S., Henriksson K.G., et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85(3):483—491.
  • 148. Olivan-Blazquez B.B., Herrera-Mercadal P., Puebla-Guedea M, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain 2014;155( 12):2517-2525.
  • 149. Khan M.A., Houck D.R., Gross A.L., et al. NYX-2925 is a novel NMDA receptor-specific spirocyclic- P-lactam that modulates synaptic plasticity processes associated with learning and memory. Ini J Neuropsychopharmacol 2018:21 (3):242—254.
  • 150. Biospace. Aptinyx announces results of phase 2 fibromyalgia study of NYX-2925 have been selected for late-breaking presentation at the American college of rheumatology annual meeting. 2019. https:// www.biospace.com/article/releases/aptinyx-announces-results-of-phase-2-fibrornyalgia-study-of-nyx- 2925-have-been-selected-for-late-breaking-presentation-at-the-american-college-of-rheumatology- annual-meeting. Accessed 02 December 2019.
  • 151. Pridgen W.L., Duffy C„ Gendreau J.F., Gendreau R.M. A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. J Pain Res 2017;10:451-460.
  • 152. Russo E.B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2008:29(2): 192-200.
  • 153. Skrabek R.Q., Galirnova L., Ethans K., Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008:9(2): 164-173.
  • 154. Ware M.A., Fitzcharles M.A., Joseph L., Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110(2):604—610.
  • 155. Fiz J., Duran M, Capella D.. Carbonell J., Farre M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE 201 l;6(4):el8440.
  • 156. Sagy I., Bar-Lev Schleider L., Abu-Shakra M., Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med 2019;8(6):807.
  • 157. Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-l-tryptophan: a 90-day open study. J Int Med Res 1992:20(2): 182-189.
  • 158. Caruso I., Sarzi Puttini P, Cazzola M., Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18(3):201—209.
  • 159. Tavoni A., Vitali C., Bombardieri S., Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med 1987;83(5A): 107-110.
  • 160. Jacobsen S„ Danneskiold-Samspe B., Andersen R.B. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991 ;20(4):294—302.
  • 161. Volkmann H„ Nprregaard J., Jacobsen S., et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol 1997;26(3):206—211.
  • 162. Tavoni A., Jeracitano G., Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. Clin Exp Rheumatol 1998;16( 1): 106—107.
  • 163. Rx.list. St. John’s Wort, https://www.rxlist.com/st_johns_wort/supplements.htm. Accessed 17 August
  • 2020.
  • 164. Shils M., Olson A., Shike M. Modern Nutrition in Health and Disease, 8th ed. Philadelphia, PA: Lea and Febiger, 1994.
  • 165. Russell I.J., Michalek J.E., Flechas J.D., Abraham G.E. Treatment of fibromyalgia syndrome with super malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol 1995;22(5):953—958.
  • 166. Bagis S., Karabiber M., As I., et al. Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia? Rheumatol Int 2013;33(1): 167—172.
  • 167. Greenberg S., Frishman W.H. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30(7):596-608.
  • 168. Cordero M.D., Alcocer-Gomez E., de Miguel M., et al. Can coenzyme Q10 improve clinical and molecular parameters in fibromyalgia? Anlioxid Redox Signal 2013;19(12):1356—1361.
  • 169. Lister R.E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002;30(2): 195-199.
  • 170. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336(3):186—195.
  • 171. Citera G., Arias M.A., Maldonado-Cocco J.A., et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000;19( 1):9—13.
  • 172. Lawson K. Is there a role for melatonin in fibromyalgia. J Clin Med 2019;8:807.
  • 173. American Family Physician. Panax ginseng. Am Fam Physician 2003; 68(8): 1539—1542.
  • 174. Braz A.S., Morais L.C., Paula A.P., Diniz M.F., Almeida R.N. Effects of panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial. Rev Bras Psiquiatr 2013;35( 1 ):21—28.
  • 175. Teitelbaum J.E., Johnson C., St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Ahern Complement Med 2006:12(9):857—862.
  • 176. Wepner F., Scheuer R., Schuetz-Wieser B., et al. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. Pain 2014;155(2):261—268.
  • 177. Vidal-Casariego A., Burgos-Pelaez R., Martfnez-Faedo C., Calvo-Gracia F., Valero-Zanuy M.A., Luengo-Perez L.M., Cuerda-Compes C. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes 2013;121(4):234—238.
  • 178. Rossini M., Di Munno O., Valentini G., et al. Double-blind, multicenter trial comparing acetyl l-carni- tine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 2007;25(2):182—188.
  • 179. Leombruni P, Miniotti M., Colonna F., et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol 2015;33(1 Suppl 88):S82-S85.
  • 180. Russell I.J., Orr M.D., Littman B., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37( 11): 1593—1601.
  • 181. McCarty D.J., Csuka M., McCarthy G., et al. Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 1994;23(6):41—47.
  • 182. Natural Medicines. Natural medicines in the clinical management of fibromyalgia. http://naturaldataba se.therapeuticresearch. com. pitt.idm. oclc.org/ce/CECourse. aspx?cs=naturalstandard&s=ND&pm=5 &pc=17-108. Accessed 27 December 2017.
  • 183. Zhang F., Altorki N.K., Mestre J.R., Subbaramaiah K., Dannenberg A.J. Curcumin inhibits cyclooxy- genase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999;20(3):445—451.
  • 184. Sosa-Reina M.D., Nunez-Nagy S., Gallego-Izquierdo T., Pecos-Martin D., Monserrat J., Alvarez-Mon M. Effectiveness of therapeutic exercise in fibromyalgia syndrome: a systematic review and meta-anal- ysis of randomized clinical trials. BioMed Res hit 2017:2017:2356346.
  • 185. Mungufa-Izquierdo D., Legaz-Arrese A. Assessment of the effects of aquatic therapy on global symptomatology in patients with fibromyalgia syndrome: a randomized controlled trial. Arch Phys Med Rehabil 2008;89(12):2250—2257.
  • 186. Bernardy K., Klose P, Busch A.J., Choy E.H., Hauser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev 2013;10(9):CD009796.
  • 187. Alda M., Luciano J.V., Andres E., et al. Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in patients with fibromyalgia: a randomised controlled trial. Arthritis Res Ther 2011;13(5):R173.
  • 188. Mist S.D., Firestone K.A., Dupree-Jones K. Complementary and alternative exercise for fibromyalgia: a meta-analysis. J Pain Res 2013;6:247-260.
  • 189. Cheng C.A., Chiu Y.W., Wu D.. Kuan Y.C., Chen S.N.. Tam K.W. Effectiveness of Tai Chi on fibromyalgia patients: a meta-analysis of randomized controlled trials. Complement Ther Med 2019;46:1-8.
  • 190. Chen K.W., Hassett A.L., Hou F., Staller J., Lichtbroun A.S. A pilot study of external qigong therapy for patients with fibromyalgia. J Altern Complement Med 2006; 12(9):851-856.
  • 191. Stephens S., Feldman B.M., Bradley N., et al. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum 2008;59( 10): 1399-1406.
  • 192. Kim J., Kim S.-R., Hyangsook L., Dong-Hyun N. Comparing verum and sham acupuncture in fibromyalgia syndrome: a systemic review and meta-analysis. Evid Based Complement Alternat Med 2019^8757685. doi: 10.1155/2019/8757685.
 
<<   CONTENTS   >>

Related topics